Silence is not always Golden: Should we perform catheter ablation in asymptomatic atrial fibrillation? Clinical debate and emerging evidence
Progress in Cardiovascular Diseases · 2025
DOI: 10.1016/j.pcad.2025.10.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Progress in Cardiovascular Diseases, 2025. Verfasst von Marco Schiavone und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Heart Rate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Atrial fibrillation (AF) is a growing global health burden and a leading cause of morbidity and mortality. A significant proportion of AF episodes are asymptomatic or subclinical, leading to underdiagnosis and delayed treatment. Despite traditionally reserving rhythm control-particularly catheter ablation-for symptomatic patients, emerging evidence suggests that asymptomatic individuals face similar risks of stroke, heart failure, and AF progression. Recent data challenge the assumption that asymptomatic AF represents a benign phenotype. Meta-analyses and registry studies show comparable rates of adverse outcomes between symptomatic and asymptomatic patients and highlight AF progression as more frequent in the latter group, if left untreated. Randomized trials such as EAST-AFNET 4 and multiple ablation-first studies (e.g., EARLY-AF, Cryo-FIRST) support early rhythm control, with a growing rationale to consider it even in the absence of symptoms. Furthermore, pulsed field ablation (PFA) represents a transformative innovation, offering tissue-selective, non-thermal lesion creation with promising early clinical data. While routine ablation for all asymptomatic patients is not yet guideline-recommended, evolving evidence and improved safety profiles support a more proactive rhythm control strategy in selected individuals. Shared decision-making, grounded in risk stratification and patient-specific factors, is essential. As new data emerge, the case for expanding ablation indications to include asymptomatic AF continues to strengthen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino IRCCS, Milan, Italy.
- Cardiac Arrhythmia Center, Division of Cardiology at Montefiore-Einstein Center, Bronx, NY, USA. Electronic address: dibbia@gmail.com.
Zitieren
APA
Schiavone, M., & Di Biase, L. (2025). Silence is not always Golden: Should we perform catheter ablation in asymptomatic atrial fibrillation? Clinical debate and emerging evidence. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2025.10.004
Vancouver
Schiavone M, Di Biase L. Silence is not always Golden: Should we perform catheter ablation in asymptomatic atrial fibrillation? Clinical debate and emerging evidence. Progress in Cardiovascular Diseases. 2025. doi:10.1016/j.pcad.2025.10.004
BibTeX
@article{Schiavone2025,
author = {Schiavone, Marco and Di Biase, Luigi},
title = {Silence is not always Golden: Should we perform catheter ablation in asymptomatic atrial fibrillation? Clinical debate and emerging evidence},
journal = {Progress in Cardiovascular Diseases},
year = {2025},
doi = {10.1016/j.pcad.2025.10.004}
}
EUVIMED